Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response and toxicity rate of two different
dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in
haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).